DexComDXCM
DXCM
About: Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Employees: 9,600
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
5% less call options, than puts
Call options by funds: $404M | Put options by funds: $423M
5% less repeat investments, than reductions
Existing positions increased: 325 | Existing positions reduced: 343
7.25% less ownership
Funds ownership: 95.28% [Q2] → 88.03% (-7.25%) [Q3]
12% less funds holding
Funds holding: 982 [Q2] → 867 (-115) [Q3]
36% less funds holding in top 10
Funds holding in top 10: 14 [Q2] → 9 (-5) [Q3]
45% less capital invested
Capital invested by funds: $42.9B [Q2] → $23.7B (-$19.3B) [Q3]
54% less first-time investments, than exits
New positions opened: 98 | Existing positions closed: 213
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$85
6%
upside
Avg. target
$96
20%
upside
High target
$115
44%
upside
9 analyst ratings
8 positive
89%
1 neutral
11%
0 negative
0%
Citigroup Joanne Wuensch 55% 1-year accuracy 26 / 47 met price target | 14%upside $91 | Buy Maintained | 11 Dec 2024 |
Wells Fargo Larry Biegelsen 51% 1-year accuracy 24 / 47 met price target | 17%upside $94 | Overweight Maintained | 11 Dec 2024 |
Canaccord Genuity William Plovanic 57% 1-year accuracy 26 / 46 met price target | 24%upside $99 | Buy Maintained | 9 Dec 2024 |
Bernstein Lee Hambright 50% 1-year accuracy 3 / 6 met price target | 7%upside $86 | Outperform Maintained | 25 Oct 2024 |
Raymond James Jayson Bedford 66% 1-year accuracy 19 / 29 met price target | 24%upside $99 | Strong Buy Maintained | 25 Oct 2024 |
Financial journalist opinion
Based on 16 articles about DXCM published over the past 30 days
Neutral
The Motley Fool
18 hours ago
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
Shares of the medical-device maker DexCom (DXCM 5.57%) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a massive drop in its stock price overnight.
Positive
Zacks Investment Research
1 day ago
2025 Picks: 2 Stocks to Buy Now for 50% Upside
Two S&P 500 stocks--DexCom and Albemarle--are already on sale for investors to buy in 2025.
Neutral
Business Wire
2 days ago
Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement
NEW YORK--(BUSINESS WIRE)--EDO, the TV outcomes company, has released its Q3 2024 Diabetes Convergent TV Outcomes Report, providing critical insights into the diabetes category linear and streaming TV ad performance. The report reveals actionable findings on what drives consumer engagement in this category, with GLP-1 drugs reshaping the landscape of diabetes management and advertisers increasingly investing in convergent TV to target this growing audience. Consumer engagement – measured by act.
Positive
Zacks Investment Research
3 days ago
DXCM Stock Gains on the Launch of Proprietary Generative AI Platform
Dexcom announces the first Generative AI platform in glucose biosensing.
Positive
CNBC
4 days ago
Dexcom's over-the-counter glucose monitor now offers users an AI summary of how sleep, meals and more impact sugar levels
Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI platform with technology from Google Cloud.
Neutral
Business Wire
4 days ago
Dexcom Launches the First Generative AI Platform in Glucose Biosensing
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to integrate GenAI into glucose biosensing technology.1 The new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health. Stelo,.
Neutral
Business Wire
4 days ago
Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the eligibility criteria* to also include adults ages 18 and older. Alberta residents living with type 1 or type 2 diabetes who are enrolled in a government-sponsored health benefit plan† and.
Positive
Zacks Investment Research
1 week ago
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM continues to raise optimism among investors owing to its strong product portfolio.
Positive
Seeking Alpha
1 week ago
DexCom: Brighter 2025 From Stelo Ramp
DexCom faces challenges in 2024 due to competition and missteps, but the long-term outlook for continuous glucose monitors remains strong. Q3 revenue grew only 2% y/y to $994.2 million, with temporary and long-lasting headwinds impacting growth and margins. The new over-the-counter Stelo CGM launched in August, offering a new growth vector and targeting non-insulin users, with significant ramp-up expected in 2025.
Positive
Seeking Alpha
2 weeks ago
11 Ultra SWAN Bargains That Could Thrive As The Market Soars To Record Highs
The S&P is up 27% in 2024, including a 5.5% rally in November. The Euphoria index is at record highs, indicating investor sentiment is extremely bullish. While 2025 is likely to see much larger volatility, there are still many excellent blue-chip opportunities to buy for a potentially significant 2025. Here are 11 Ultra Sleep Well At Night quality companies that are 45% undervalued, growing at 18%, with an 85% average fundamentally justified return potential in 2025.
Charts implemented using Lightweight Charts™